Hemorrhagic and thrombotic complications in bone marrow transplant recipients

Thrombosis Research

Volumn 120, Issue SUPPL. 2, 2007, Pages

  Nadir, Yona ^a   Brenner, Benjamin ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Central venous lines thrombosis; Diffuse alveolar hemorrhage; Hemorrhagic cystitis; Stem cell transplantation; Veno occlusive disease

Indexed keywords

ALTEPLASE; ANTITHROMBIN III; CORTICOSTEROID; DEFIBROTIDE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; URSODEOXYCHOLIC ACID;

ARTICLE; BLEEDING; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HEMOSTASIS; HUMAN; LIVER VENOOCCLUSIVE DISEASE; LUNG HEMORRHAGE; MORBIDITY; MORTALITY; NONHUMAN; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOSIS; VEIN OCCLUSION; VEIN THROMBOSIS;

BONE MARROW TRANSPLANTATION; HEMORRHAGE; HUMANS; THROMBOSIS;

EID: 36048958520     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(07)70136-6     Document Type: Article

References (98)

1. Nadir Y., Hoffman R., and Brenner B. Drug-related thrombosis in hematologic malignancies. Rev Clin Exp Hematol 8 (2004) E4
2. Piguet P., Grau G., Collart M., Vassalli P., and Kapanci Y. Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab Invest 61 (1989) 37-45
3. Gordon B., Haire W., Kessinger A., Duggan M., and Armitage J. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 8 (1991) 497-502
4. Scrobohaci M., Drouet L., Monem-Mansi A., Devergie A., Baudin B., D'Agay M., et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res 63 (1991) 509-519
5. Leblond V., Salehian B., Borel C., Mapakou C., Dombret H., Sutton L., et al. Alterations in natural anticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients. Bone Marrow Transplant 11 (1993) 299-305
6. Faioni E., Krachmalnicoff A., Bearman S., Federici A., Decarli A., Gianni A., et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 81 (1993) 3458-3462
7. Collins P., Roderick A., O'Brien D., Tuddenham E., O'Driscoll A., Chopra R., et al. Factor VIIa and other haemostatic variables following bone marrow transplantation. Thromb Haemost 72 (1994) 28-32
8. Collins P., Gutteridge C., O'Driscoll A., Blair S., Jones L., Aitchison R., et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant 10 (1992) 499-506
9. Salat C., Holler E., Reinhardt B., Kolb H., Seeber B., Ledderose G., et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 14 (1994) 747-750
10. Sharma S., Nadrous H., Peters S., Tefferi A., Litzow M., Aubry M., et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 128 (2005) 1385-1392
11. Metcalf J., Rennard S., Reed E., Haire W., Sisson J., Walter T., et al. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group. Am J Med 96 (1994) 327-334
12. Sisson J., Thompson A., Anderson J., Robbins R., Spurzem J., Spence P., et al. Airway inflammation predicts diffuse alveolar hemorrhage during bone marrow transplantation in patients with Hodgkin disease. Am Rev Respir Dis 146 (1992) 439-443
13. Witte R., Gurney J., Robbins R., Linder J., Rennard S., Arneson M., et al. Diffuse pulmonary alveolar hemorrhage after bone marrow transplantation: radiographic findings in 39 patients. AJR Am J Roentgenol 157 (1991) 461-464
14. Crilley P., Topolsky D., Styler M., Bernstein E., Resnick K., Mullaney R., et al. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. Bone Marrow Transplant 15 (1995) 361-365
15. Ho V., Weller E., Lee S., Alyea E., Antin J., and Soiffer R. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7 (2001) 223-229
16. Baker W., Vukelja S., Burrell L., Lee N., and Perry J. High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results. Bone Marrow Transplant 21 (1998) 775-778
17. Chao N., Duncan S., Long G., Horning S., and Blume K. Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Ann Intern Med 114 (1991) 145-146
18. Frankovich J., Donaldson S., Lee Y., Wong R., Amylon M., and Verneris M. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant 7 (2001) 49-57
19. Majhail N., Parks K., Defor T., and Weisdorf D. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 12 (2006) 1038-1046
20. Majhail N., Parks K., Defor T., and Weisdorf D. Alveolar hemor-rhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Bone Marrow Transplant 38 (2006) 765-768
21. Jules-Elysee K., Stover D., Yahalom J., White D., and Gulati S. Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation. Am Rev Respir Dis 146 (1992) 485-491
22. Robbins R., Linder J., Stahl M., Thompson III A., Haire W., et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 87 (1989) 511-518
23. Sloane J., Depledge M., Powles R., Morgenstern G., Trickey B., and Dady P. Histopathology of the lung after bone marrow transplantation. J Clin Pathol 36 (1983) 546-554
24. Wojno K., Vogelsang G., Beschorner W., and Santos G. Pulmonary hemorrhage as a cause of death in allogeneic bone marrow recipients with severe acute graft-versus-host disease. Transplantation 57 (1994) 88-92
25. Beschorner W., Shinn C., Hess A., Suresch D., and Santos G. Immune-related injury to endothelium associated with acute graft-versus-host disease in the rat. Transplant Proc 21 (1989) 3025-3027
26. Corso S., Vukelja S., Wiener D., and Baker W. Diffuse alveolar hemorrhage following autologous bone marrow infusion. Bone Marrow Transplant 12 (1993) 301-303
27. Mulder P., Meinesz A., de Vries E., and Mulder N. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 90 (1991) 278-281
28. Meng Z., Dyer K., Billiar T., and Tweardy D. Distinct effects of systemic infusion of G-CSF vs. IL-6 on lung and liver inflammation and injury in hemorrhagic shock. Shock 14 (2000) 41-48
29. Haselton D., Klekamp J., Christman B., and Barr F. Use of high-dose corticosteroids and high-frequency oscillatory ventilation for treatment of a child with diffuse alveolar hemorrhage after bone marrow transplantation: case report and review of the literature. Crit Care Med 28 (2000) 245-248
30. Raptis A., Mavroudis D., Suffredini A., Molldrem J., Rhee F., Childs R., et al. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 24 (1999) 879-883
31. Srivastava A., Gottlieb D., and Bradstock K. Diffuse alveolar haemorrhage associated with microangiopathy after allo-geneic bone marrow transplantation. Bone Marrow Transplant 15 (1995) 863-867
32. Blatt J., Gold S., Wiley J., Monahan P., Cooper H., and Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 28 (2001) 405-407
33. Brenner B., Hoffman R., Balashov D., Shutluko E., Culic S., and Nizamoutdinova E. Control of bleeding caused by thrombo-cytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost 11 (2005) 401-410
34. Pihusch M., Bacigalupo A., Szer J., von Depka Prondzinski M., Gaspar-Blaudschun B., Hyveled L., et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 3 (2005) 1935-1944
35. Bedi A., Miller C., Hanson J., Goodman S., Ambinder R., Charache P., et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 13 (1995) 1103-1109
36. Lima M., Ferreira F., Macedo F., de Castro Brito G., and Ribeiro R. Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis. Cancer Chemother Pharmacol 59 (2007) 643-650
37. Azzi A., Cesaro S., Laszlo D., Zakrzewska K., Ciappi S., De Santis R., et al. Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients. J Clin Virol 14 (1999) 79-86
38. Seber A., Shu X., Defor T., Sencer S., and Ramsay N. Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant 23 (1999) 35-40
39. Mori T., Aisa Y., Shimizu T., Ikeda Y., Okamoto S., Okada K., et al. Hemorrhagic cystitis caused by adenovirus type 34 after allogeneic bone marrow transplantation. Transplantation 79 (2005) 624
40. Andrei G., Fiten P., Goubau P., van Landuyt H., Gordts B., Selleslag D., et al. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient. Transpl Infect Dis 9 (2007) 126-131
41. Giraud G., Bogdanovic G., Priftakis P., Remberger M., Svahn B., Barkholt L., et al. The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica 91 (2006) 401-404
42. Efros M., Ahmed T., Coombe N., and Choudhury M. Urologic complications of high-dose chemotherapy and bone marrow transplantation. Urology 43 (1994) 355-360
43. Heath J., Mishra S., Mitchell S., Waters K., and Tiedemann K. Estrogen as treatment of hemorrhagic cystitis in children and adolescents undergoing bone marrow transplantation. Bone Marrow Transplant 37 (2006) 523-526
44. Hattori K., Yabe M., Matsumoto M., Kudo Y., Yasuda Y., Inoue H., et al. Successful hyperbaric oxygen treatment of life-threatening hemorrhagic cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 27 (2001) 1315-1317
45. Karimi M., Zakerinia M., Khojasteh H., Ramzi M., and Ahmad E. Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven) after allogenic bone marrow transplantation. J Thromb Haemost 2 (2004) 1853-1855
46. McDonald G., Sharma P., Matthews D., Shulman H., and Thomas E. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4 (1984) 116-122
47. Bearman S. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 85 (1995) 3005-3020
48. Richardson P., and Guinan E. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol 107 (1999) 485-493
49. Richardson P., and Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol 106 (2001) 57-68
50. Carreras E., Bertz H., Arcese W., Vernant J., Tomas J., Hagglund H., et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92 (1998) 3599-3604
51. McDonald G., Hinds M., Fisher L., Schoch H., Wolford J., Banaji M., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118 (1993) 255-267
52. Shulman H., Fisher L., Schoch H., Henne K., and McDonald G. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 19 (1994) 1171-1181
53. DeLeve L., Shulman H., and McDonald G. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22 (2002) 27-42
54. Bearman S., Anderson G., Mori M., Hinds M., Shulman H., and McDonald G. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 11 (1993) 1729-1736
55. Shulman H., Gown A., and Nugent D. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 127 (1987) 549-558
56. DeLeve L. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 24 (1996) 830-837
57. Hassan M., Ljungman P., Ringden O., Hassan Z., Oberg G., Nilsson C., et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25 (2000) 915-924
58. de Jonge M., Huitema A., Beijnen J., and Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 94 (2006) 1226-1230
59. el Mouelhi M., and Kauffman F. Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver. Hepatology 6 (1986) 450-456
60. Deleve L. Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 268 (1994) 1261-1270
61. Teicher B., Crawford J., Holden S., Lin Y., Cathcart K., Luchette C., et al. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide. Cancer 62 (1988) 1275-1281
62. Nurnberger W., Michelmann I., Burdach S., and Gobel U. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 76 (1998) 61-65
63. Pihusch V., Pihusch M., Penovici M., Kolb H., Hiller E., and Pihusch R. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb Res 116 (2005) 233-240
64. Anscher M., Peters W., Reisenbichler H., Petros W., and Jirtle R. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 328 (1993) 1592-1598
65. Ferra C., de Sanjose S., Gallardo D., Berlanga J., Rueda F., Marin D., et al. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica 83 (1998) 1082-1087
66. Duggan C., Schmidt M., Lawler M., White B., Cusack S., McCann S., et al. The prothrombin gene variant G20210A but not factor V Leiden may be associated with veno-occlusive disease following BMT. Bone Marrow Transplant 24 (1999) 693-694
67. Ertem M., and Akar N. Factor V Leiden mutation as a predisposing factor for veno-occlusive disease following BMT. Bone Marrow Transplant 25 (2000) 1110-1111
68. Ohashi K., Tanabe J., Watanabe R., Tanaka T., Sakamaki H., Maruta A., et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 64 (2000) 32-38
69. Essell J., Thompson J., Harman G., Halvorson R., Snyder M., Callander N., et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant 10 (1992) 367-372
70. Essell J., Schroeder M., Harman G., Halvorson R., Lew V., Callander N., et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128 (1998) 975-981
71. Ruutu T., Eriksson B., Remes K., Juvonen E., Volin L., Remberger M., et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 100 (2002) 1977-1983
72. Attal M., Huguet F., Rubie H., Huynh A., Charlet J., Payen J., et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 79 (1992) 2834-2840
73. Or R., Nagler A., Shpilberg O., Elad S., Naparstek E., Kapelushnik J., et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 61 (1996) 1067-1071
74. Simon M., Hahn T., Ford L., Anderson B., Swinnich D., Baer M., et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 27 (2001) 627-633
75. Park S., Lee M., Lee H., Kim H., Kim K., Kim W., et al. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 29 (2002) 137-143
76. Forrest D., Thompson K., Dorcas V., Couban S., and Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant 31 (2003) 1143-1149
77. Richardson P., and Bearman S. Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. Leuk Lymphoma 31 (1998) 267-277
78. Bearman S., Lee J., Baron A., and McDonald G. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 89 (1997) 1501-1506
79. Bajwa R., Cant A., Abinun M., Flood T., Hodges S., Hale J., et al. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment. Bone Marrow Transplant 31 (2003) 591-597
80. Wadleigh M., Richardson P., Zahrieh D., Lee S., Cutler C., Ho V., et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 102 (2003) 1578-1582
81. Richardson P., Elias A., Krishnan A., Wheeler C., Nath R., Hoppensteadt D., et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 92 (1998) 737-744
82. Chopra R., Eaton J., Grassi A., Potter M., Shaw B., Salat C., et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 111 (2000) 1122-1129
83. Abecasis M., Conceicao Silva J., Ferreira I., Guimaraes A., and Machado A. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation. Bone Marrow Transplant 23 (1999) 843-846
84. Coccheri S., Biagi G., Legnani C., Bianchini B., and Grauso F. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 35 (1988) 151-156
85. Berti F., Rossoni G., Biasi G., Buschi A., Mandelli V., and Tondo C. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins. Prostaglandins 40 (1990) 337-350
86. Zhou Q., Chu X., and Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 71 (1994) 507-510
87. Ulutin O. Antithrombotic effect and clinical potential of defibrotide. Semin Thromb Hemost 19 Suppl 1 (1993) 186-191
88. Falanga A., Vignoli A., Marchetti M., and Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 17 (2003) 1636-1642
89. Palmer K., and Goa K. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 45 (1993) 259-294
90. Koehl G., Geissler E., Iacobelli M., Frei C., Burger V., Haffner S., et al. Defibrotide: An Endothelium Protecting and Stabilizing Drug, has an Anti-Angiogenic Potential In Vitro and In Vivo. Cancer Biol Ther (2007) 6
91. Richardson P., Murakami C., Jin Z., Warren D., Momtaz P., Hoppensteadt D., et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 100 (2002) 4337-4343
92. Haussmann U., Fischer J., Eber S., Scherer F., Seger R., and Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 91 (2006) 795-800
93. Dignan F., Gujral D., Ethell M., Evans S., Treleaven J., Morgan G., et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 40 (2007) 79-82
94. Lagro S., Verdonck L., Borel Rinkes I., and Dekker A. No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients. Bone Marrow Transplant 26 (2000) 1103-1106
95. Abdelkefi A., Ben Romdhane N., Kriaa A., Chelli M., Torjman L., Ladeb S., et al. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients. Bone Marrow Transplant 36 (2005) 885-889
96. Chiusolo P., Sica S., De Stefano V., Casorelli I., Laurenti L., and Leone G. Incidence of Factor V Leiden and prothrombin G20210A in patients submitted to stem cell transplantation. Haematologica 85 (2000) 670-671
97. Biffi R., De Braud F., Orsi F., Pozzi S., Arnaldi P., Goldhirsch A., et al. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 92 (2001) 1204-1212
98. Verso M., Agnelli G., Bertoglio S., Di Somma F., Paoletti F., Ageno W., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23 (2005) 4057-4062